Belvedere Trading
INBX

Belvedere Trading’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Belvedere Trading’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,682
Closed -$216K – 1105
2023
Q4 		$216K Buy
+5,682
New +$122K ﹤0.01% 325

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Belvedere Trading's INBX Position: Q1 2024 in Review

Belvedere Trading sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 5,682 shares — an estimated $216K sold.

Belvedere Trading first reported a position in INBX in Q4 2023 and held it in 1 quarter. The position peaked at $216K in Q4 2023. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Belvedere Trading reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Belvedere Trading sold 5,682 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $216K.
  • Belvedere Trading first reported a position in Inhibrx, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Belvedere Trading's Inhibrx, Inc. Common Stock position peaked at $216K in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.